Aldeyra Therapeutics, Inc. (FRA:137)
Germany
· Delayed Price · Currency is EUR 4.011
-0.145 (-3.49%)
At close: Dec 5, 2025
Aldeyra Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 59.34 | 54.53 | 142.82 | 144.42 | 104.79 | 52.86 | Upgrade
|
| Short-Term Investments | 15.96 | 46.62 | - | 29.88 | - | - | Upgrade
|
| Cash & Short-Term Investments | 75.3 | 101.15 | 142.82 | 174.3 | 104.79 | 52.86 | Upgrade
|
| Cash Growth | 3.51% | -29.18% | -18.06% | 66.33% | 98.25% | 16.52% | Upgrade
|
| Other Receivables | - | - | - | 3.24 | 0.03 | - | Upgrade
|
| Receivables | - | - | - | 3.24 | 125.03 | 25 | Upgrade
|
| Prepaid Expenses | 1.03 | 0.71 | 0.52 | 0.87 | 0.53 | 0.41 | Upgrade
|
| Other Current Assets | 1.13 | 2.21 | 4.46 | 2.61 | 2.4 | 4.79 | Upgrade
|
| Total Current Assets | 77.46 | 104.07 | 147.81 | 181.02 | 232.75 | 83.06 | Upgrade
|
| Property, Plant & Equipment | 0.34 | 0.27 | 0.52 | 0.27 | 0.38 | 0.29 | Upgrade
|
| Long-Term Deferred Charges | - | 0.27 | - | - | - | - | Upgrade
|
| Total Assets | 77.8 | 104.61 | 148.33 | 181.29 | 233.14 | 83.35 | Upgrade
|
| Accounts Payable | 0.01 | 0.18 | 1.34 | 0.13 | 1.02 | 0.38 | Upgrade
|
| Accrued Expenses | 7 | 12.12 | 5.54 | 14.07 | 10.52 | 5.63 | Upgrade
|
| Current Portion of Long-Term Debt | 15.2 | 0.03 | 15.15 | 0.91 | - | 3.66 | Upgrade
|
| Current Portion of Leases | 0.27 | 0.27 | 0.24 | 0.25 | 0.23 | 0.23 | Upgrade
|
| Current Unearned Revenue | 6 | 6 | - | - | - | - | Upgrade
|
| Other Current Liabilities | - | - | - | - | - | 2.5 | Upgrade
|
| Total Current Liabilities | 28.48 | 18.6 | 22.26 | 15.36 | 11.77 | 12.41 | Upgrade
|
| Long-Term Debt | - | 15 | - | 14.92 | 15.5 | 11.43 | Upgrade
|
| Long-Term Leases | 0.07 | - | 0.27 | - | 0.13 | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | 6 | - | - | - | Upgrade
|
| Total Liabilities | 28.56 | 33.6 | 28.53 | 30.28 | 27.4 | 23.84 | Upgrade
|
| Common Stock | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 526.68 | 521.02 | 513.99 | 507.77 | 500.37 | 296.39 | Upgrade
|
| Retained Earnings | -477.5 | -450.11 | -394.26 | -356.72 | -294.69 | -236.92 | Upgrade
|
| Comprehensive Income & Other | 0 | 0.04 | - | -0.1 | - | - | Upgrade
|
| Shareholders' Equity | 49.24 | 71 | 119.8 | 151.01 | 205.74 | 59.51 | Upgrade
|
| Total Liabilities & Equity | 77.8 | 104.61 | 148.33 | 181.29 | 233.14 | 83.35 | Upgrade
|
| Total Debt | 15.54 | 15.3 | 15.66 | 16.08 | 15.86 | 15.33 | Upgrade
|
| Net Cash (Debt) | 59.75 | 85.85 | 127.17 | 158.22 | 88.93 | 37.53 | Upgrade
|
| Net Cash Growth | 4.59% | -32.49% | -19.63% | 77.91% | 136.96% | 22.61% | Upgrade
|
| Net Cash Per Share | 1.00 | 1.44 | 2.16 | 2.71 | 1.65 | 1.10 | Upgrade
|
| Filing Date Shares Outstanding | 60.16 | 59.71 | 58.9 | 58.58 | 58.1 | 47.25 | Upgrade
|
| Total Common Shares Outstanding | 60.16 | 59.65 | 59.2 | 58.56 | 58.08 | 38.67 | Upgrade
|
| Working Capital | 48.98 | 85.47 | 125.55 | 165.66 | 220.98 | 70.65 | Upgrade
|
| Book Value Per Share | 0.82 | 1.19 | 2.02 | 2.58 | 3.54 | 1.54 | Upgrade
|
| Tangible Book Value | 49.24 | 71 | 119.8 | 151.01 | 205.74 | 59.51 | Upgrade
|
| Tangible Book Value Per Share | 0.82 | 1.19 | 2.02 | 2.58 | 3.54 | 1.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.